litlas
Log inCreate account

Daniel G. Haller

Active 1979–2025

86
Papers
32,809
Citations
79
h-index
85
i10-index

Citations

Citations per year for Daniel G. Haller1982: 1 citations1983: 1 citations1984: 1 citations1985: 2 citations1986: 4 citations1987: 7 citations1988: 4 citations1989: 3 citations1990: 5 citations1991: 10 citations1992: 21 citations1993: 14 citations1994: 24 citations1995: 22 citations1996: 28 citations1997: 51 citations1998: 58 citations1999: 57 citations2000: 53 citations2001: 100 citations2002: 130 citations2003: 142 citations2004: 196 citations2005: 283 citations2006: 271 citations2007: 291 citations2008: 291 citations2009: 268 citations2010: 306 citations2011: 310 citations2012: 243 citations2013: 219 citations2014: 239 citations2015: 217 citations2016: 178 citations2017: 175 citations2018: 125 citations2019: 579 citations2020: 560 citations2021: 424 citations2022: 289 citations2023: 194 citations2024: 306 citations2025: 83 citations2026: 3 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,133 citing papers, 27.4% of this breakdownChina: 679 citing papers, 8.7% of this breakdownUnited Kingdom: 531 citing papers, 6.8% of this breakdownItaly: 423 citing papers, 5.4% of this breakdownGermany: 386 citing papers, 5% of this breakdownJapan: 370 citing papers, 4.7% of this breakdownFrance: 369 citing papers, 4.7% of this breakdownNetherlands: 305 citing papers, 3.9% of this breakdownCanada: 274 citing papers, 3.5% of this breakdownSpain: 215 citing papers, 2.8% of this breakdownAustralia: 210 citing papers, 2.7% of this breakdownSouth Korea: 202 citing papers, 2.6% of this breakdown
0%27.4%Other 21.8%

Institutions

Fields

  • Medicine80.8%
  • Biochemistry, Genetics and Molecular Biology12.8%
  • Immunology and Microbiology1.7%
  • Materials Science0.7%
  • Mathematics0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other2.8%

Topics

  • Colorectal Cancer Surgical Treatments8.2%
  • Colorectal Cancer Treatments and Studies8%
  • Gastric Cancer Management and Outcomes6%
  • Colorectal Cancer Screening and Detection4.3%
  • Genetic factors in colorectal cancer4.1%
  • Pancreatic and Hepatic Oncology Research3.8%
  • Other65.6%

Coauthors

All papers

Open in search
  1. Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Authors: Daniel J. Sargent, Alberto Sobrero, Axel Grothey, Michael J. O’Connell, Marc Buyse, Thierry André, Yan Zheng, Erin Green, Roberto Labianca, Chris J. O’Callaghan, Jean François Seitz, Guido Francini, Daniel G. Haller, Greg Yothers, Richard M. Goldberg, Aimery de Gramont - Journal of Clinical Oncology 2009 cited by 676

  2. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials

    Authors: Romain Cohen, Julien Taı̈eb, Jack Fiskum, Greg Yothers, Richard M. Goldberg, Takayuki Yoshino, Steven R. Alberts, Carmen J. Allegra, Aimery de Gramont, J. F. Seitz, Michael J. O’Connell, Daniel G. Haller, Norman Wolmark, Charles Erlichman, Alberto Zaniboni, Sara Lonardi, Rachel Kerr, Axel Grothey, Frank A. Sinicrope, Thierry André, Qian Shi - Journal of Clinical Oncology 2020 cited by 172

  3. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction

    Authors: John S. Macdonald, Stephen R. Smalley, Jacqueline Benedetti, Scott A. Hundahl, Norman Estes, Grant N. Stemmermann, Daniel G. Haller, Jaffer A. Ajani, Leonard L. Gunderson, J. Milburn Jessup, James A. Martenson - New England Journal of Medicine 2001 cited by 3,509

  4. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

    Authors: Daniel G. Haller, Josep Tabernero, Jean A. Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Frank Gilberg, Karen Rittweger, Hans‐Joachim Schmoll - Journal of Clinical Oncology 2011 cited by 789

  5. Colon Cancer Survival Is Associated With Increasing Number of Lymph Nodes Analyzed: A Secondary Survey of Intergroup Trial INT-0089

    Authors: Thomas E. Le Voyer, Elin R. Sigurdson, Alexandra L. Hanlon, Robert J. Mayer, J. S. Macdonald, Paul J. Catalano, Daniel G. Haller - Journal of Clinical Oncology 2003 cited by 1,159

  6. Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma

    Authors: Charles G. Moertel, Thomas R. Fleming, John S. Macdonald, Daniel G. Haller, John A. Laurie, Phyllis J. Goodman, James S. Ungerleider, William A. Emerson, Douglas C. Tormey, John H. Glick, Michael H. Veeder, James A. Mailliard - New England Journal of Medicine 1990 cited by 2,258

  7. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

    Authors: Demetris Papamichael, Riccardo A. Audisio, Bengt Glimelius, Aimery de Gramont, Rob Glynne‐Jones, Daniel G. Haller, Claus Henning Köhne, Siri Rostoft, V.E.P.P. Lemmens, Emmanuel Mitry, H.J.T. Rutten, Daniel J. Sargent, Javier Sastre, Michel Seymour, Naureen Starling, E. Van Cutsem, Matti Aapro - Annals of Oncology 2014 cited by 463

  8. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial

    Authors: Hans‐Joachim Schmoll, Josep Tabernero, Jean A. Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Silke Hoersch, Karen Rittweger, Daniel G. Haller - Journal of Clinical Oncology 2015 cited by 302

  9. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Authors: Daniel J. Sargent, Harry S. Wieand, Daniel G. Haller, Richard Gray, Jacqueline Benedetti, Marc Buyse, Roberto Labianca, Jean François Seitz, Christopher J. O’Callaghan, Guido Francini, Axel Grothey, Michael J. O’Connell, Paul J. Catalano, Charles D. Blanke, David Kerr, Erin Green, Norman Wolmark, Thierry André, Richard M. Goldberg, Aimery de Gramont - Journal of Clinical Oncology 2005 cited by 712

  10. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

    Authors: Al B. Benson, Deborah Schrag, Mark R. Somerfield, Alfred M. Cohen, A Figueredo, Patrick J. Flynn, Monika K. Krzyzanowska, Jean A. Maroun, Pamela K. McAllister, Eric Van Cutsem, Melissa Brouwers, Manya Charette, Daniel G. Haller - Journal of Clinical Oncology 2004 cited by 1,451

  11. Adjuvant Active Specific Immunotherapy for Stage II and III Colon Cancer With an Autologous Tumor Cell Vaccine: Eastern Cooperative Oncology Group Study E5283

    Authors: Jules E. Harris, Louise Ryan, Herbert Hoover, Robert K. Stuart, Martin M. Oken, Al B. Benson, Edward G. Mansour, Daniel G. Haller, Judith Manola, Michael G. Hanna - Journal of Clinical Oncology 2000 cited by 272

  12. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database

    Authors: Dorothea Wagner, Axel Grothey, Thierry André, Jesse G. Dixon, Norman Wolmark, Daniel G. Haller, Carmen J. Allegra, Aimery de Gramont, Eric VanCutsem, Steven R. Alberts, Thomas J. George, Michael J. O’Connell, Christopher Twelves, Julien Taı̈eb, Leonard B. Saltz, Charles D. Blanke, Edoardo Francini, Rachel Kerr, Greg Yothers, Jean François Seitz, Silvia Marsoni, Richard M. Goldberg, Qian Shi - JNCI Journal of the National Cancer Institute 2020 cited by 86

  13. Colon Cancer Survival Is Associated With Decreasing Ratio of Metastatic to Examined Lymph Nodes

    Authors: Adam C. Berger, Elin R. Sigurdson, Thomas E. LeVoyer, Alexandra L. Hanlon, Robert J. Mayer, John S. Macdonald, Paul J. Catalano, Daniel G. Haller - Journal of Clinical Oncology 2005 cited by 517

  14. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

    Authors: Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony F. Shields, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Frank A. Sinicrope, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A. Meyerhardt, Thierry André, Demetris Papamichael, Julien Taı̈eb - Journal of Clinical Oncology 2022 cited by 50

  15. Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

    Authors: Stephen R. Smalley, Jacqueline Benedetti, Daniel G. Haller, Scott A. Hundahl, Norman Estes, Jaffer A. Ajani, Leonard L. Gunderson, Bryan Goldman, James A. Martenson, J. Milburn Jessup, Grant N. Stemmermann, Charles D. Blanke, John S. Macdonald - Journal of Clinical Oncology 2012 cited by 857

  16. Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database

    Authors: Nadine J. McCleary, Jeffrey A. Meyerhardt, Erin Green, Greg Yothers, Aimery de Gramont, Eric Van Cutsem, Michael J. O’Connell, Christopher Twelves, Leonard B. Saltz, Daniel G. Haller, Daniel J. Sargent - Journal of Clinical Oncology 2013 cited by 266

  17. Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer

    Authors: David P. Kelsen, Robert J. Ginsberg, Thomas F. Pajak, Daniel G. Sheahan, Leonard L. Gunderson, Joanne Mortimer, Norman Estes, Daniel G. Haller, Jaffer A. Ajani, Walter Kocha, Bruce D. Minsky, Jack A. Roth - New England Journal of Medicine 1998 cited by 1,361

  18. Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?

    Authors: Sharlene Gill, Charles L. Loprinzi, Daniel J. Sargent, Stephan D. Thomé, Steven R. Alberts, Daniel G. Haller, Jacqueline Benedetti, Guido Francini, Lois E. Shepherd, Jean François Seitz, Roberto Labianca, Wei Chen, Stephen S. Cha, Michael P. Heldebrant, Richard M. Goldberg - Journal of Clinical Oncology 2004 cited by 1,015

  19. A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients

    Authors: Daniel J. Sargent, Richard M. Goldberg, Stacy D. Jacobson, John S. Macdonald, Roberto Labianca, Daniel G. Haller, Lois E. Shepherd, Jean François Seitz, Guido Francini - New England Journal of Medicine 2001 cited by 994

  20. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials

    Authors: Hans‐Joachim Schmoll, Chris Twelves, Weijing Sun, Michael J. O’Connell, Thomas H. Cartwright, Edward McKenna, Muhammad Wasif Saif, Steve Lee, Greg Yothers, Daniel G. Haller - The Lancet Oncology 2014 cited by 168

  21. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database

    Authors: Manish A. Shah, Lindsay A. Renfro, Carmen J. Allegra, Thierry André, Aimery de Gramont, Hans‐Joachim Schmoll, Daniel G. Haller, Steven R. Alberts, Greg Yothers, Daniel J. Sargent - Journal of Clinical Oncology 2016 cited by 165

  22. Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

    Authors: Jordan Berlin, Paul J. Catalano, James P. Thomas, John W. Kugler, Daniel G. Haller, Al B. Benson - Journal of Clinical Oncology 2002 cited by 730

  23. Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer

    Authors: David P. Kelsen, Katryn A. Winter, Leonard L. Gunderson, Joanne Mortimer, Norman Estes, Daniel G. Haller, Jaffer A. Ajani, Walter Kocha, Bruce D. Minsky, Jack A. Roth, Christopher G. Willett - Journal of Clinical Oncology 2007 cited by 541

  24. Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

    Authors: Elizabeth Poplin, Yang Feng, Jordan Berlin, Mace L. Rothenberg, Howard S. Höchster, Edith P. Mitchell, Steven R. Alberts, Peter J. O’Dwyer, Daniel G. Haller, Paul J. Catalano, David Cella, Al B. Benson - Journal of Clinical Oncology 2009 cited by 432